SI0862431T1 - Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate - Google Patents

Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate

Info

Publication number
SI0862431T1
SI0862431T1 SI9630410T SI9630410T SI0862431T1 SI 0862431 T1 SI0862431 T1 SI 0862431T1 SI 9630410 T SI9630410 T SI 9630410T SI 9630410 T SI9630410 T SI 9630410T SI 0862431 T1 SI0862431 T1 SI 0862431T1
Authority
SI
Slovenia
Prior art keywords
amoxycillin
paediatric
clavulanate
pharmaceutical formulation
formulation
Prior art date
Application number
SI9630410T
Other languages
English (en)
Slovenian (sl)
Inventor
Daniel Joseph Burch
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21705455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0862431(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of SI0862431T1 publication Critical patent/SI0862431T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SI9630410T 1995-09-07 1996-09-05 Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate SI0862431T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US335395P 1995-09-07 1995-09-07
EP96930817A EP0862431B1 (fr) 1995-09-07 1996-09-05 Utilisaton d'une preparation pharmaceutique pediatrique contenant de l'amoxicilline et du clavulanate
PCT/US1996/014554 WO1997009042A1 (fr) 1995-09-07 1996-09-05 Preparation pharmaceutique

Publications (1)

Publication Number Publication Date
SI0862431T1 true SI0862431T1 (en) 2002-06-30

Family

ID=21705455

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630410T SI0862431T1 (en) 1995-09-07 1996-09-05 Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate

Country Status (28)

Country Link
US (3) US6726908B2 (fr)
EP (3) EP1147771A1 (fr)
JP (1) JP3501289B2 (fr)
KR (1) KR100495585B1 (fr)
CN (1) CN1289084C (fr)
AR (1) AR004510A1 (fr)
AT (1) ATE208618T1 (fr)
AU (1) AU711441B2 (fr)
BR (1) BR9610396A (fr)
CA (1) CA2231194C (fr)
CO (1) CO4750658A1 (fr)
CY (1) CY2359B1 (fr)
CZ (1) CZ299595B6 (fr)
DE (1) DE69617036T2 (fr)
DK (1) DK0862431T3 (fr)
ES (1) ES2165997T3 (fr)
HK (2) HK1015701A1 (fr)
HU (1) HUP9901437A3 (fr)
IL (1) IL123563A (fr)
NO (1) NO314831B1 (fr)
NZ (3) NZ337247A (fr)
PL (1) PL325411A1 (fr)
PT (1) PT862431E (fr)
SI (1) SI0862431T1 (fr)
TR (1) TR199800415T1 (fr)
TW (1) TW501926B (fr)
WO (1) WO1997009042A1 (fr)
ZA (1) ZA967546B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EP1147771A1 (fr) 1995-09-07 2001-10-24 Smithkline Beecham Corporation Composition pharmaceutique contenant de l'amoxicilline et du clavulanate
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
DE10017883A1 (de) * 1999-04-13 2000-10-26 Beecham Pharm Pte Ltd Neues Behandlungsverfahren
GB2365337A (en) * 1999-04-13 2002-02-20 Beecham Pharma Amoxycillin and potassium clavulanate high dosage regimen
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
WO2001000177A1 (fr) * 1999-06-29 2001-01-04 Micio Pharma Chemical Aktiengesellschaft Formulation retard d'amoxicilline administree par voie orale
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (fr) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
WO2013057569A2 (fr) 2011-10-19 2013-04-25 Micro Labs Limited Composition pharmaceutique à libération prolongée contenant de l'amoxicilline et de l'acide clavulanique
BR112014016850A8 (pt) * 2012-01-10 2017-07-04 Hoberman Alejandro composição líquida para o tratamento de otite media pediátrica, suspensão oral pediátrica, método de tratamento de otite média pediátrica em pacientes com menos de 24 meses de idade e método de tratamento de haemophilus influenzae, e moraxella catarrhalis produtoras de beta-lactamase em pacientes pediátricos com menos de 24 meses de idade
WO2013173808A2 (fr) * 2012-05-17 2013-11-21 Michael Spector Procédés d'utilisation de compositions à dose plus faible d'amoxicilline et de clavulanate de potassium et dispositifs d'utilisation
WO2013173803A2 (fr) * 2012-05-17 2013-11-21 Michael Spector Formulations d'amoxicilline et de clavulanate de potassium et procédés d'utilisation de celles-ci
EP3364955B1 (fr) 2015-10-09 2022-04-20 RB Health (US) LLC Formulation pharmaceutique

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en) 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
US4673637A (en) 1984-04-23 1987-06-16 Hyman Edward S Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria
ES2061623T3 (es) 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5114929A (en) 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
KR910009271B1 (ko) 1989-06-20 1991-11-08 김영설 1,1-디옥소페닐실라노일 옥시메틸 D-6-[α-(메틸렌아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
US5814337A (en) * 1992-10-07 1998-09-29 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9114950D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation
WO1994016696A1 (fr) * 1993-01-22 1994-08-04 Smithkline Beecham Plc Formulations pharmaceutiques comprenant de l'acide clavulanique seul ou associe a d'autres beta-lactamines
GB9311030D0 (en) 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9405856D0 (en) 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9416599D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
DZ2028A1 (fr) 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US5830073A (en) 1995-07-28 1998-11-03 Voss; Brian C. Bowling lane surfaces
EP1147771A1 (fr) * 1995-09-07 2001-10-24 Smithkline Beecham Corporation Composition pharmaceutique contenant de l'amoxicilline et du clavulanate
ID23673A (id) 1997-02-14 2000-05-11 Smithkline Beecham Lab Pharma Formulasi farmasi yang terdiri dari amoksicilin dan klavulanat
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
ID22340A (id) 1997-03-25 1999-09-30 Takeda Chemical Industries Ltd Komposisi farmasi lekat-mukosa saluran pencernaan
GB9815532D0 (en) 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
DE10017883A1 (de) * 1999-04-13 2000-10-26 Beecham Pharm Pte Ltd Neues Behandlungsverfahren

Also Published As

Publication number Publication date
ES2165997T3 (es) 2002-04-01
EP1093812A3 (fr) 2001-06-06
JP3501289B2 (ja) 2004-03-02
NZ318282A (en) 2000-01-28
CO4750658A1 (es) 1999-03-31
DE69617036D1 (de) 2001-12-20
US6726908B2 (en) 2004-04-27
CN1289084C (zh) 2006-12-13
EP0862431B1 (fr) 2001-11-14
US20010043926A1 (en) 2001-11-22
NZ337247A (en) 2001-05-25
CZ299595B6 (cs) 2008-09-17
HUP9901437A3 (en) 2000-03-28
EP0862431A4 (fr) 1999-07-07
TW501926B (en) 2002-09-11
PT862431E (pt) 2002-04-29
US20010038838A1 (en) 2001-11-08
CA2231194C (fr) 2004-07-20
AU6973396A (en) 1997-03-27
EP0862431A1 (fr) 1998-09-09
CZ68398A3 (cs) 1998-07-15
DK0862431T3 (da) 2002-03-11
US20050261267A1 (en) 2005-11-24
EP1147771A1 (fr) 2001-10-24
NO981008D0 (no) 1998-03-06
TR199800415T1 (en) 1998-05-21
ATE208618T1 (de) 2001-11-15
CA2231194A1 (fr) 1997-03-13
BR9610396A (pt) 1999-07-06
KR100495585B1 (ko) 2005-09-09
NO314831B1 (no) 2003-06-02
HK1043042A1 (zh) 2002-09-06
DE69617036T2 (de) 2002-07-11
AU711441B2 (en) 1999-10-14
HUP9901437A2 (hu) 1999-09-28
CY2359B1 (en) 2004-06-04
ZA967546B (en) 1998-03-06
JPH11512398A (ja) 1999-10-26
PL325411A1 (en) 1998-07-20
AR004510A1 (es) 1998-12-16
NZ337246A (en) 2000-07-28
NO981008L (no) 1998-05-06
MX9801903A (es) 1998-05-31
CN1200672A (zh) 1998-12-02
IL123563A (en) 2002-02-10
HK1015701A1 (en) 1999-10-22
KR19990044495A (ko) 1999-06-25
EP1093812A2 (fr) 2001-04-25
WO1997009042A1 (fr) 1997-03-13

Similar Documents

Publication Publication Date Title
SI0862431T1 (en) Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
HK1050992A1 (zh) 含有藥物配方的阿莫西林和克拉維酸
IL131201A (en) Pharmaceutical formulations comprising amoxycillin and clavulanate
AU3777597A (en) Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient
AU5538098A (en) A slow releasing physiologically active pharmaceutical and method of preparation thereof
AU6042696A (en) Drug delivery catheters and methods of use
AU5171293A (en) Ion-pairing of drugs for improved efficacy and delivery
AU6501296A (en) Method and apparatus of enhancing the delivery of a pharmaceutical formulation
AU4022697A (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia
HK1009101A1 (en) Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients
AU2230692A (en) Pharmaceutical formulation of a beta-lactam antibiotic and clavulanic acid or a water-soluble salt thereof
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
IL102003A0 (en) Pharmaceutical formulation of a benzodiazepine
AU6318896A (en) Benzamidoxime derivatives and medicinal use thereof
AU5739499A (en) Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate
AU3363193A (en) Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivative
GB9304745D0 (en) Use of pharmaceutical formulations
ZA951789B (en) Pharmaceutical materials and methods of administration
AU5841696A (en) Preparation and use of contrast agents
ZA948192B (en) Pharmaceutical formulation of aspirin and sallcylates
SI0825860T1 (en) Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients
AU1401895A (en) Triflate-mediated preparation and use of iodonium compounds
ZA969474B (en) Potentiation of analgesic anti-inflammatory and anti-pyrit-ic drugs
GB9507677D0 (en) Pharmaceutical formulation and dose
HUP0001584A3 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate